Cytokinetics, Incorporated
CYTK
$39.48
$0.330.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.03% | -9.43% | -1.05% | -23.17% | -35.30% |
| Total Depreciation and Amortization | -19.85% | 86.87% | 90.96% | 95.78% | 104.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 53.14% | 12.98% | -15.15% | -12.07% | -10.52% |
| Change in Net Operating Assets | 1,054.55% | 255.63% | 306.98% | 95.92% | 112.50% |
| Cash from Operations | 4.45% | 7.78% | 6.39% | -6.72% | -38.33% |
| Capital Expenditure | -175.85% | 40.74% | 79.24% | 90.61% | 87.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -328.19% | -309.53% | -12,806.61% | 598.13% | 195.96% |
| Cash from Investing | -331.18% | -313.02% | -3,947.48% | 428.81% | 191.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,020.98% | -834.68% | 96.99% | 98.88% | 99.55% |
| Issuance of Common Stock | 315.92% | 5,241.68% | 4,740.00% | 1,676.77% | 941.40% |
| Repurchase of Common Stock | -86.66% | -75.42% | -75.42% | -75.42% | -9.53% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 300.00% | 161.81% | 847.26% | 89.45% | -71.19% |
| Cash from Financing | 320.49% | 1,231.31% | 175.12% | -19.96% | -57.12% |
| Foreign Exchange rate Adjustments | 1,145.00% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.31% | -755.68% | 593.57% | 240.38% | 201.61% |